ITAS is the first randomized controlled trial specifically comparing the efficacy and safety of initiation and titration of Gla‐300 managed by either the patient (nurse‐assisted) or physician, in an insulin‐naïve population with uncontrolled T2DM, after withdrawal of SU/glinides. The gene discussed is INS; the disease is type 2 diabetes mellitus.